Case Study: Dose Optimization for Bi-Specifics & Tri-Specifics
- How MIDD helps define rational starting doses for complex biologics
- Compare strategies for dose selection in multi-target modalities
- How modeling is supporting faster and safer advancement of novel immunotherapies